ECM
HUMA icon

ExodusPoint Capital Management’s Humacyte HUMA Stock Holding History

ExodusPoint Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,081
Closed -$21K – 1749
2025
Q2 		$21K Sell
10,081
-141,773
-93% -$272K ﹤0.01% 1383
2025
Q1 		$259K Buy
+151,854
New +$570K ﹤0.01% 1258
2022
Q2 		– Sell
-105,525
Closed -$745K – 2146
2022
Q1 		$745K Buy
+105,525
New +$614K 0.01% 1318

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

ExodusPoint Capital Management's HUMA Position: Q3 2025 in Review

ExodusPoint Capital Management sold out of Humacyte (HUMA) in Q3 2025, closing a stake of 10,081 shares — an estimated $21K sold.

ExodusPoint Capital Management first reported a position in HUMA in Q1 2022 and held it in 3 quarters. The position peaked at $745K in Q1 2022. 141 funds tracked by Wall St. Rank hold HUMA as of Q3 2025.

  • ExodusPoint Capital Management reported no remaining Humacyte position as of Q3 2025 after selling out during the quarter.
  • ExodusPoint Capital Management sold 10,081 Humacyte shares in Q3 2025, an estimated $21K.
  • ExodusPoint Capital Management first reported a position in Humacyte in Q1 2022 and held it in 3 quarters.
  • ExodusPoint Capital Management's Humacyte position peaked at $745K in Q1 2022.
  • 141 funds tracked by Wall St. Rank held Humacyte as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.